Slide 1: FY Results 2022
FY Results 2022 Zur Rose Group Walter Hess | Marcel Ziwica | Madhu Nutakki 23 March 2023
Slide 2: Today's presenters
Today’s presenters Walter Hess Group CEO Zur Rose Group Marcel Ziwica Group CFO FY results 2022 Madhu Nutakki Group CTO
Slide 3: Agenda
Agenda . Highlights Business update Pure focus on B2C with DocMorris digital health ecosystem Financial update: Path to profitability Outlook Q&A DB oo pe ‘Zur Rose Group FY results 2022
Slide 4: Highlights: Key messages
Highlights Key messages All targets 2022 reached and milestones delivered Convincing signals for nationwide roll-out of EUR 50bn eRx within second half of 2023 Sale of Swiss business significantly strengthens balance sheet Adj. EBITDA break-even (excl. eRx) moved to 2024, following sale of Swiss bus
Slide 5: Highlights
Highlights 1External revenue consists of the consolidated revenue of the Zur Rose Group plus mail order revenues of pharmacies supplied by the Zur Rose Group, less the consolidated revenue from supplying them | 2in local currency | 3CPP: Cost per parcel | 4excluding sale of real estate
Slide 6: Agenda
Agenda Highlights . Business update Pure focus on B2C with DocMorris digital health ecosystem Financial update: Path to profitability Outlook Q&A ed i E> 9 [S) ‘Zur Rose Group FY results 2022
Slide 7: Business update
Business update 1KIM: electronic letters between healthcare providers (German: Kommunikation im Medizinwesen) | 2eGK: electronic health insurance card (German: elektronische Gesundheitskarte)
Slide 8: Business update
Business update 1https://www.bundesgesundheitsministerium.de/themen/krankenversicherung/zahlen-und-fakten-zur-krankenversicherung/finanzergebnisse.html | 2IQVIA | 3Sveriges Apoteksforening: Swedish pharmacy sector report 2022 | 4wissenschaftliches Institut der AOK 2020 | 5Kantarstudie and YouGov Bra
Slide 9: Business update: becomes DocMorris
Business update Zur Rose Group becomes DocMorris DocMotrris — DocMorris brand for corporate and business — Zur Rose Group (holding company) will be renamed into DocMorris AG! — Headquarters to remain in Switzerland — Listing to remain on SIX Swiss exchange — Customer centric, lean organisational str
Slide 10: Hybrid brand strategy for Germany
Business update Hybrid brand strategy for Germany with DocMorris as core brand to cater to the needs of specific customer segments @ DocMorris apot Brand category Core brand Sub-brand Sub-brand Positioning Digital health Feel good Discountpharmacy ecosystem pharmacy Key target groups Chronic patient
Slide 11: Significantly advanced sustainability agenda in 2022
Business update Significantly advanced sustainability agenda in 2022 and clear targets tied to executive compensation Healthier People — Launch of two Chronic Care paths — Industry-leader: Drug safety notes and telemedicine Sustainable Planet — Optimised logistics with new distribution centre — Comm
Slide 12: Agenda
Agenda 1. Highlights 2. Business update 3. Pure focus on B2C with DocMorris digital health ecosystem 4. Financial update: Path to profitability 5. Outlook 6. Q&A ‘Zur Rose Group FYresults 2022 12
Slide 13: DocMorris digital health ecosystem addresses German market challenges
B2C core business DocMorris digital health ecosystem is the solution for multiple challenges of the German healthcare and pharmacy market German healthcare industry challenges — Increasing treatment needs due to chronic diseases — Public budget deficit >EUR 20bn in 2024 — Lack of digitalisation acro
Slide 14: DocMorris digital health ecosystem
B2C core business To deliver the most efficient, empathetic healthcare imaginable. For everyone. Anywhere. In one click. DocMorris digital health ecosystem Chronic Care ePharmacy Zur Rose Group FY results 2022 Centred around users, fulfilling the needs and wishes of patients and customers Making car
Slide 15: B2C core business
B2C core business − − − − − − − − − − − − − − −
Slide 16: B2C core business
B2C core business DocMorris medpex Others DocMorris medpex Others DocMorris medpex Others Shop Shop Shop Shop / Patient Services Shop Shop Shop Messaging/API/Services Messaging/API/Services Logistics Logistics Logistics Logistics Logistics Unified Logistics [ Heerlen ] Technology Technology Culture
Slide 17: Focus on science for clear, actionable signals
B2C core business Focus on science for clear, actionable signals to drive value customer. SCIENCE SCIENCE roduct. CIENCE behavioural. SCIENCE Zur Rose Group Influence business outcomes by acting on reliable leading indicators Increase profitability for every customer through algorithms on pricing an
Slide 18: Successful transformation journey
B2C core business Successful and exciting transformation journey to put patient happiness at the centre of everything we do — Digital transformation of architecture, product and culture — Focus on science for clear, actionable signals to drive better outcomes internally and externally — Preferred di
Slide 19: Agenda
Agenda 1. Highlights 2. Business update 3. Pure focus on B2C with DocMorris digital health ecosystem 4. Financial update: Path to profitability 5. Outlook 6. Q&A ‘Zur Rose Group FYresults 2022
Slide 20: Financial update: Path to profitability
Financial update: Path to profitability − − −
Slide 21: Financial update: Path to profitability
Financial update: Path to profitability
Slide 22: Financial update: Path to profitability
Financial update: Path to profitability
Slide 23: Financial update: Path to profitability
Financial update: Path to profitability − − − −
Slide 24: Financial update: Path to profitability
Financial update: Path to profitability − − − − − − − −
Slide 25: Active customers, repeat order rate, basket size
Financial update: Path to profitability Active customers1 Repeat order rate2 Site visits3 in m H1 2021 FY 2021 H1 2022 FY 2022 H1 2021 FY 2021 H1 2022 FY 2022 Basket size4 Order frequency5 in EUR Rx OTC 11.7 12.4 11.7 10.4 117 128 125 115 4.0 3.7 3.9 4.0 40 39 39 40 2.0 2.1 2.1 2.1 H1 2021 FY 2021 H
Slide 26: FY 2022 in CHF m
Financial update: Path to profitability FY 2022 Margin FY 2021 Margin in yoy in CHF m in % % % External revenue 1,836.7 2,034.0 (9.7) Consolidated revenue 1,608.2 1,726.5 (6.9) Gross profit adj. 246.8 15.3 263.0 15.2 (6.2) Personnel expenses adj. (148.1) (9.2) (143.1) (8.3) (3.5) Marketing expenses
Slide 27: Balance sheet and cash
Financial update: Path to profitability 31 Dec 2022 % 31 Dec 2021 % in CHF m Cash and cash equivalents 156.0 277.7 Receivables 156.3 166.5 Inventories 83.2 92.5 Property, plant & equipment 96.8 98.7 Intangible assets 571.9 595.4 Other assets 35.2 38.4 Total assets 1,099.4 1,269.2 Financial liabiliti
Slide 28: Agenda
Agenda 1. Highlights 2. Business update 3. Pure focus on B2C with DocMorris digital health ecosystem 4. Financial update: Path to profitability: Break-even programme update 5. Outlook 6. Q&A ‘Zur Rose Group FYresults 2022 28
Slide 29: Group outlook
Group outlook − − − 1External revenue consists of the consolidated revenue of the Zur Rose Group plus mail order revenues of pharmacies supplied by the Zur Rose Group, less the consolidated revenue from supplying them. | 2Chart not to scale
Slide 30: Group outlook
Group outlook 1External revenue consists of the consolidated revenue of the Zur Rose Group plus mail order revenues of pharmacies supplied by the Zur Rose Group, less the consolidated revenue from supplying them.
Slide 31: Agenda
Agenda Highlights Business update Pure focus on B2C with DocMorris digital health ecosystem Financial update: Path to profitability . Outlook 6. Q&A a BON ‘Zur Rose Group FYresults 2022 BL
Slide 32: Q&A
Q&A ‘Zur Rose Group FY results 2022 32
Slide 33: Note: Where dates are not shown, timings are indicative
Note: Where dates are not shown, timings are indicative
Slide 34: Disclaimer
Disclaimer This presentation (the "Presentation") has been prepared by Zur Rose Group AG ("Zur Rose" and together with its subsidiaries, "we", "us" or the "Group") solely for informational purposes and has not been independently verified and no representation or warranty, express or implied, is made